AG
TNGX icon

Algert Global’s Tango Therapeutics TNGX Stock Holding History

Algert Global’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.49M Buy
271,570
+125,930
+86% +$3.11M 0.1% 328
2026
Q1 		$3.05M Buy
+145,640
New +$2.03M 0.05% 596
2025
Q2 		– Sell
-65,560
Closed -$89.8K – 1347
2025
Q1 		$89.8K Sell
65,560
-96,740
-60% -$238K ﹤0.01% 1134
2024
Q4 		$502K Buy
+162,300
New +$754K 0.01% 908
2023
Q3 		– Sell
-40,088
Closed -$133K – 1255
2023
Q2 		$133K Hold
40,088
– – 0.01% 1021
2023
Q1 		$158K Sell
40,088
-2,385
-6% -$13.8K 0.01% 1045
2022
Q4 		$308K Buy
42,473
+8,050
+23% +$56.6K 0.02% 927
2022
Q3 		$125K Buy
34,423
+17,453
+103% +$74.5K 0.01% 1088
2022
Q2 		$77K Buy
+16,970
New +$103K 0.01% 1134

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Algert Global's TNGX Position: Q2 2026 in Review

Algert Global increased its Tango Therapeutics (TNGX) stake by 86% in Q2 2026, buying an estimated $3.11M and bringing the position to 271,570 shares worth $8.49M. The position accounts for 0.1% of the portfolio, ranked #328.

Algert Global first reported a position in TNGX in Q2 2022 and has held it in 9 quarters since. 249 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Algert Global held 271,570 shares of Tango Therapeutics worth $8.49M as of Q2 2026.
  • Algert Global bought 125,930 Tango Therapeutics shares in Q2 2026, an estimated $3.11M.
  • Tango Therapeutics made up 0.1% of Algert Global's portfolio in Q2 2026, its #328 holding.
  • Algert Global first reported a position in Tango Therapeutics in Q2 2022 and has held it in 9 quarters since.
  • 249 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.